[ad_1]
“The idea is that we want to demonstrate proof of concept, which is [vakcina] effective for people, ”Nadavas Kidron, director of Oramed, told the publication.
“Imagine that you can receive the vaccine orally and everything: a person has been vaccinated. It would be a revolution for everyone,” he emphasized.
It is announced that Oramed’s subsidiary, Oravax Medical, with the approval of the Ministry of Health, is preparing to conduct clinical trials of its vaccine at the Suraskis Medical Center in Tel Aviv. Such a permit is expected to be issued in the coming weeks.
According to The Jerusalem Post, Oravax has already manufactured several thousand oral vaccine capsules in Europe in accordance with Good Manufacturing Practice (GMP) standards. It is these capsules that will be used in clinical trials in Israel and later in some other countries.
Under the company’s plans, the study will involve 24 people who have not been vaccinated with any other COVID-19 vaccine. Half of the participants will receive one capsule of oral vaccine and the other half will receive two. It should be noted that placebo will not be used in studies lasting six weeks.
The head of Oravax said that if these studies were successful, he would first seek authorization for the emergency use of the vaccine in the countries that need it most, such as South America.
Kidron emphasized that the vaccine, whose development was announced in March, “targeted” three structural proteins of the coronavirus immediately and caused the production of type A and G antibodies, without the need for special transport and storage conditions.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
